Reviva announces enrollment completion for pivotal phase 3 recover study for brilaroxazine in schizophrenia

- 402 patients completed enrollment across multiple sites in the us, europe, and asia – - topline data for phase 3 recover study expected in october 2023 - - completion of 1-year open-label extension clinical study expected in q3 2024 - cupertino, calif., aug. 17, 2023 (globe newswire) -- reviva pharmaceuticals holdings, inc. (nasdaq: rvph) (“reviva” or the “company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (cns), inflammatory and cardiometabolic diseases, today announced that enrollment is complete in the pivotal phase 3 recover study evaluating brilaroxazine for schizophrenia, with 402 patients enrolled at multiple sites in the united states (~60%), europe (~10%), and asia (~30%).
RVPH Ratings Summary
RVPH Quant Ranking